|
May 15
|
Liquidia Corp (LQDA) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ...
|
|
May 15
|
Q1 2024 Liquidia Corp Earnings Call
|
|
May 14
|
Liquidia (NASDAQ:LQDA) shareholders have earned a 64% CAGR over the last three years
|
|
May 14
|
Down -11.26% in 4 Weeks, Here's Why You Should You Buy the Dip in Liquidia Technologies (LQDA)
|
|
May 13
|
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 10
|
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
|
|
May 7
|
Liquidia Corporation to Present at BofA Securities Health Care Conference 2024
|
|
May 7
|
Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024
|
|
Apr 26
|
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
|
|
Apr 25
|
Earnings Preview: Liquidia Technologies, Inc. (LQDA) Q1 Earnings Expected to Decline
|
|
Apr 24
|
When Will Liquidia Corporation (NASDAQ:LQDA) Become Profitable?
|
|
Apr 3
|
Liquidia Corporation (NASDAQ:LQDA) has caught the attention of institutional investors who hold a sizeable 38% stake
|
|
Apr 2
|
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
|
|
Apr 1
|
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
|
|
Mar 20
|
Chief Medical Officer Rajeev Saggar Sells Shares of Liquidia Corp (LQDA)
|
|
Mar 20
|
Insider Sell: CFO and COO Michael Kaseta Sells 12,166 Shares of Liquidia Corp (LQDA)
|
|
Mar 16
|
Liquidia Corporation (NASDAQ:LQDA) Q4 2023 Earnings Call Transcript
|
|
Mar 14
|
Liquidia Full Year 2023 Earnings: Misses Expectations
|
|
Mar 14
|
Q4 2023 Liquidia Corp Earnings Call
|
|
Mar 13
|
Liquidia Corp (LQDA) Reports Full Year 2023 Financial Results
|